文献速递冠心病

新型口服P2Y12抑制剂在男女急性冠脉综合征患者中的相对与绝对疗效差异:荟萃分析与建模研究

Differences in relative and absolute effectiveness of oral P2Y 12 inhibition in men and women: a meta-analysis and modelling study.
PubMed 文献 · Heart · 2017-10-05

该研究通过荟萃分析9项随机对照试验并结合苏格兰2006至2010年急性心肌梗死住院队列,评估新型P2Y12抑制剂(替格瑞洛、普拉格雷)对比氯吡格雷在男女急性冠脉综合征患者中的相对与绝对疗效。结果显示男性主要不良心血管事件治疗率比为0.80(95%CI 0.69-0.93),女性为0.86(95%CI 0.72-1.04),性别-治疗交互作用率比为1.08(95%CI 0.98-1.19);将性别特异性率比应用于队列后,男女1年全因、心血管及出血死亡的绝对风险降低相似。

要点

  • 新型P2Y12抑制剂在男性中相对疗效更明确,女性可能略低但绝对风险降低相似。
  • 男性主要不良心血管事件治疗率比0.80(95%CI 0.69-0.93),女性0.86(95%CI 0.72-1.04)。
  • 男女1年全因死亡绝对风险降低分别为2.47%和2.30%,差异无统计学意义。

核心结论

  • 新型P2Y12抑制剂在女性中相对疗效可能略低于男性,但男女绝对风险降低相似。

主要发现

  • 3项对比新型P2Y12抑制剂与氯吡格雷的急性冠脉综合征试验中,男性主要不良心血管事件治疗率比为0.80(95%CI 0.69-0.93)。
  • 全部9项试验中,性别-治疗交互作用率比为1.08(95%CI 0.98-1.19),结合后女性治疗率比为0.86(95%CI 0.72-1.04)。
  • 女性全因死亡率32.0%(5708例)、心血管死亡率22.6%(4032例)、出血死亡率1.1%(193例),均高于男性的21.2%(5891例)、14.8%(4117例)和0.8%(228例)。
  • 将性别特异性率比应用于队列后,男女1年全因死亡绝对风险降低分别为2.47%(95%CI 0.62%-4.10%)和2.30%(95%CI -0.92%-5.22%)。
  • 心血管死亡绝对风险降低男性为2.72%(95%CI 0.92%-4.35%),女性为2.70%(95%CI -0.63%-5.74%);出血死亡绝对风险降低男性为-0.18%(95%CI -0.71%-0.24%),女性为-0.27%(95%CI -1.06%-0.30%)。

临床怎么用

  • 临床决策中不应因性别差异而限制女性使用新型P2Y12抑制剂,因男女绝对风险降低相似。
  • 对女性急性冠脉综合征患者,需权衡略低的相对疗效与相似的绝对获益,并结合出血风险个体化选择。

局限性

  • 女性治疗率比由男性率比与性别-治疗交互作用率比间接推算,置信区间宽且包含无效值。
  • 建模所用死亡率来自2006至2010年苏格兰心肌梗死住院患者,早于替格瑞洛和普拉格雷的广泛应用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To estimate the absolute treatment effects of newer P2Y12 inhibitors (ticagrelor and prasugrel) compared with clopidogrel in men and women with acute coronary syndrome (ACS). METHODS: We searched Ovid MEDLINE, Embase and the Cochrane Central Register of Controlled Trials for randomised controlled trials of oral P2Y12 inhibitors for acute stroke or ACS. Age-specific and sex-specific mortality was obtained for all patients admitted to hospital with myocardial infarction in Scotland from 2006 to 2010 (prior to introduction of prasugrel or ticagrelor). RESULTS: From 9277 articles, nine fulfilled our inclusion criteria. Three trials compared newer P2Y12 inhibitors to clopidogrel in ACS, in which the treatment rate ratio (RR) for major adverse cardiovascular events in men was 0.80 (95% CI 0.69 to 0.93). For the same outcome, across all nine trials, the sex-treatment interaction RR was 1.08 (95% CI 0.98 to 1.19). Combining these estimates yielded a treatment RR in women of 0.86 (95% CI 0.72 to 1.04).17 842 women and 27 818 men were admitted to hospital with myocardial infarction. Mortality was higher for women than men for all-cause (5708, 32.0% vs 5891, 21.2%), cardiovascular (4032, 22.6% vs 4117, 14.8%) and bleeding (193, 1.1% vs 228, 0.8%) deaths.On applying the sex-specific RRs to this population, the absolute risk reduction for mortality at 1 year was similar for women and men for all-cause (2.30% (95% CI -0.92% to 5.22%) vs 2.47% (95% CI 0.62% to 4.10%)), cardiovascular (2.70% (95% CI -0.63% to 5.74%)) vs 2.72% (95% CI 0.92% to 4.35%)) and bleeding (-0.27% (95% CI -1.06% to 0.30%) vs -0.18% (95% CI -0.71% to 0.24%)) deaths. CONCLUSION: Newer P2Y12 inhibitors may be slightly less efficacious in women than men, but the absolute risk reduction is similar in both sexes.

来源:Heart,查看原文。版权归原作者所有。

引用

  1. Lee KK, Welton N, Shah AS, et al. Differences in relative and absolute effectiveness of oral P2Y 12 inhibition in men and women: a meta-analysis and modelling study. Heart. 2017. PMID: 28982722. doi:10.1136/heartjnl-2017-312003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。